Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

If you're looking for two magnificent growth stocks to start your long-term portfolio (or add to a portfolio) and have $500 ...

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price was up 1.1% during trading on Friday after Truist Financial raised their price target on the stock from $1,000.00 to $1,033.00. Truist ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

Michigan's Supreme Court reexamines rulings that may affect how the state's consumer protection laws apply to insulin pricing ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

A Washington-based surgery center ranked by a nonprofit among the top in the state for minor gender reassignment surgeries ...